...
首页> 外文期刊>Current Drug Delivery >Gastroretentive Drug Delivery System of Ranitidine Hydrochloride Based on Osmotic Technology: Development and Evaluation
【24h】

Gastroretentive Drug Delivery System of Ranitidine Hydrochloride Based on Osmotic Technology: Development and Evaluation

机译:基于渗透技术的盐酸雷尼替丁胃肠保留药物递送系统:开发与评价

获取原文
获取原文并翻译 | 示例
           

摘要

Gastroretentive drug delivery systems (GRDDS) of Ranitidine hydrochloride (RHC) has been designed based on the osmotic technology, with the floating and swelling features in order to prolong the gastric retention time. The developed system consisted of osmotic core (containing drug, osmotic agent and hydrophilic polymers), coated with semipermeable membrane (SPM) which is then further coated with compression coating of gelling agent (HPMC K4M) containing gas generating agent (citric acid). All the developed formulations were evaluated for floating lag time, duration of floating, drug content and in-vitro drug release profile. Formulation variables like levels of hydrophilic polymer (0-18.26%w/w), type of plasticizer (PEG-400, Dibutyl phthalate), coat thickness of SPM (60-100μm), were found to affect the drug release from the developed formulations. Drug release was directly proportional to hydrophilic nature of plasticizer but inversely proportional to the levels of hydrophilic polymer and coat thickness of SPM. Drug release from developed formulations was independent of level of gas generating agent in compression coat, pH and agitation intensities of release media but dependent on osmotic pressure of the release media. All the developed formulation showed floating lag time of less than 2 min (desired) and were floated for more than 12 hr. Floating lag time was inversely related to level of citric acid in compression coat and directly related to the density of the developed formulations. The manufacturing procedure was found to be reproducible and formulations were stable after 3 months accelerated stability study. Prediction of steady state levels showed the plasma concentrations of RHC to be within desired range.
机译:盐酸雷尼替丁(RHC)的胃肠道药物输送系统(GRDDS)是基于渗透技术设计的,具有漂浮和膨胀功能,以延长胃的保留时间。所开发的系统由渗透芯(包含药物,渗透剂和亲水性聚合物)组成,并涂有半透膜(SPM),然后再涂有含气体发生剂(柠檬酸)的胶凝剂(HPMC K4M)压缩涂层。评价所有开发的制剂的漂浮滞后时间,漂浮持续时间,药物含量和体外药物释放曲线。发现配方变量(如亲水性聚合物的含量(0-18.26%w / w),增塑剂的类型(PEG-400,邻苯二甲酸二丁酯),SPM的涂层厚度(60-100μm))会影响已开发配方的药物释放。药物释放与增塑剂的亲水性成正比,但与亲水性聚合物的含量和SPM的涂层厚度成反比。从开发的制剂中释放的药物与压缩衣中气体发生剂的水平,pH和释放介质的搅拌强度无关,但取决于释放介质的渗透压。所有开发的配方均显示漂浮滞后时间少于2分钟(需要),并且漂浮超过12小时。漂浮滞后时间与压缩包衣中柠檬酸的含量成反比,与所开发配方的密度成正比。经过3个月的加速稳定性研究,发现制造过程可重现且配方稳定。稳态水平的预测表明RHC的血浆浓度在所需范围内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号